Key Highlights

• Only Oral Formulation of Levosimendan in Phase 3: If successful, oral levosimendan would be the first oral formulation of an established IV heart failure inotrope to reach approval.

• PH-HFpEF Is a High Unmet Medical Need: The target indication of pulmonary hypertension with heart failure with preserved ejection fraction has very few approved effective treatments.

• Database Lock and Statistical Analysis Near Completion: The company is finalizing database lock and statistical analyses ahead of the August topline readout and ESC presentation.

The selection of Tenax Therapeutics' (NASDAQ: TENX) Phase 3 LEVEL trial data for a Late-Breaking Clinical Science session at ESC Congress 2026 in Munich on August 29 invites a closer examination of why oral levosimendan in heart failure represents a potentially significant clinical advance if the data is positive — and why the ESC's program committee deemed the results worthy of its most prestigious presentation format.

Levosimendan is an established and widely used intravenous inotrope in acute heart failure settings across Europe and other markets, acting through dual mechanisms: calcium sensitization that improves myocardial contractility without increasing oxygen demand, and potassium channel opening that produces vasodilation. However, its IV-only delivery has historically limited its use to acute hospital settings, preventing chronic outpatient maintenance therapy despite evidence of beneficial hemodynamic effects.

TNX-103, Tenax Therapeutics' (NASDAQ: TENX) oral formulation of levosimendan, is designed to deliver the same pharmacological mechanisms through once-daily oral administration, potentially enabling a chronic outpatient treatment paradigm that the current IV-only profile cannot support. In pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF), where no specifically approved treatments exist and patients face poor prognoses despite the absence of reduced ejection fraction, an orally administrable hemodynamic therapy could address a significant unmet clinical need.

The LEVEL trial enrolled patients with PH-HFpEF, a patient population that sits at the intersection of two cardiovascular conditions — pulmonary arterial hypertension and heart failure — in a way that limits the applicability of treatments specifically approved for either condition alone. Demonstrating that an oral levosimendan formulation can improve meaningful clinical outcomes in this difficult-to-treat population would be a genuinely practice-changing result.

With topline data expected in August 2026 and the ESC Congress presentation scheduled for August 29, investors in Tenax Therapeutics (NASDAQ: TENX) face a concentrated event risk window over the next several weeks. A positive topline readout would likely drive substantial share price appreciation and position the company for regulatory discussions with the FDA, while a negative result would substantially undermine the current bull thesis for the stock.

()